SOST and osteoporosis: Denosumab, a monoclonal antibody that targets RANKL, and romosozumab, a monoclonal antibody that inhibits sclerostin, have both been approved for the treatment of osteoporosis and have demonstrated significant benefits in increasing bone density and reducing fracture risk (3, 4).